Evidence map›Paper›PMID 34031614›Full record

ArticleNature immunology2021

Dynamic regulation of B cell complement signaling is integral to germinal center responses.

Arun Cumpelik, David Heja, Yuan Hu, Gabriele Varano, Farideh Ordikhani, Mark P Roberto, Zhengxiang He, Dirk Homann, Sergio A Lira, David Dominguez-Sola and 1 more

Open access · greenAbstract read
In one paragraph

Article in Nature immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 83 citations in OpenAlex.

  1. Trial
  2. Review
  3. B cells in cancer: functions, mechanisms and therapeutic advances.Signal transduction and targeted therapy · 2026
    Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Arun CumpelikRenal Division, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
David HejaRenal Division, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Yuan HuRenal Division, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Gabriele VaranoDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Farideh OrdikhaniRenal Division, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Mark P RobertoDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Zhengxiang HePrecision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-8961-859X
Dirk HomannPrecision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-7622-5754
Sergio A LiraPrecision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
David Dominguez-SolaDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. david.dominguez-sola@mssm.edu.ORCID 0000-0001-9569-8402
Peter S HeegerRenal Division, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. peter.heeger@mssm.edu.ORCID 0000-0003-4673-6913
Icahn School of Medicine at Mount Sinai · USGenesis Foundation · USTisch Hospital · USUniversity of Ferrara · IT

Funding

THE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANTP30CA196521 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Deanna L Benson · 2015 to 2026
$35.4M
TRAINING PROGRAM IN CANCER THERAPYT32CA078207 · NCI · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI James J Manfredi · 1999 to 2026
$11.6M
Mechanisms associated with flares and remission in colitisR01DK110352 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI LIRA, SERGIO A. · 2017 to 2025
$5.1M
Complement & T Cell Medicated Allograft RejectionR01AI071185 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HEEGER, PETER SCOTT · 2007 to 2016
$4.3M
Mechanisms associated with diet-induced colitisR01DK121009 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI LIRA, SERGIO A. · 2020 to 2023
$2.4M
Decay Accelerating Factor and B cell ImmunityR01AI141434 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI DOMINGUEZ-SOLA, DAVID, HEEGER, PETER SCOTT · 2019 to 2023
$2.1M
Decay accelerating factor dependent inhibition of T cell immunityR21AI126009 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HEEGER, PETER SCOTT, HOMANN, DIRK · 2016 to 2017
$466k
Complement & T Cell Medicated Allograft RejectionR56AI071185 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HEEGER, PETER SCOTT · 2012 to 2012
$339k
NCI NIH HHS P30 CA196521NCI NIH HHS T32 CA078207NIAID NIH HHS R01 AI071185NIAID NIH HHS R01 AI141434NIAID NIH HHS R21 AI126009NIAID NIH HHS R56 AI071185NIDDK NIH HHS R01 DK110352NIDDK NIH HHS R01 DK121009
6 · The paper itself

Abstract

Maturation of B cells within germinal centers (GCs) generates diversified B cell pools and high-affinity B cell antigen receptors (BCRs) for pathogen clearance. Increased receptor affinity is achieved by iterative cycles of T cell-dependent, affinity-based B cell positive selection and clonal expansion by mechanisms hitherto incompletely understood. Here we found that, as part of a physiologic program, GC B cells repressed expression of decay-accelerating factor (DAF/CD55) and other complement C3 convertase regulators via BCL6, but increased the expression of C5b-9 inhibitor CD59. These changes permitted C3 cleavage on GC B cell surfaces without the formation of membrane attack complex and activated C3a- and C5a-receptor signals required for positive selection. Genetic disruption of this pathway in antigen-activated B cells by conditional transgenic DAF overexpression or deletion of C3a and C5a receptors limited the activation of mechanistic target of rapamycin (mTOR) in response to BCR-CD40 signaling, causing premature GC collapse and impaired affinity maturation. These results reveal that coordinated shifts in complement regulation within the GC provide crucial signals underlying GC B cell positive selection.

Indexed as

Complement ActivationAnimalsAnimals, Genetically ModifiedB-LymphocytesCD55 AntigensCD59 AntigensCell Line, TumorClonal HematopoiesisComplement C3aComplement C5aGerminal CenterHumansLymphocyte ActivationMicePalatine TonsilProto-Oncogene Proteins c-bcl-6CD55 AntigensCD59 AntigensComplement C3acomplement C3a receptorComplement C5aMTOR protein, humanmTOR protein, mouseProto-Oncogene Proteins c-bcl-6Receptor, Anaphylatoxin C5aReceptors, Antigen, B-CellReceptors, ComplementTOR Serine-Threonine Kinases

Identifiers

PMID34031614
PMCPMC8297556
OpenAlexW3165536920

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.